[go: up one dir, main page]

CY1112658T1 - Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d - Google Patents

Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d

Info

Publication number
CY1112658T1
CY1112658T1 CY20121100147T CY121100147T CY1112658T1 CY 1112658 T1 CY1112658 T1 CY 1112658T1 CY 20121100147 T CY20121100147 T CY 20121100147T CY 121100147 T CY121100147 T CY 121100147T CY 1112658 T1 CY1112658 T1 CY 1112658T1
Authority
CY
Cyprus
Prior art keywords
antigenous
mague
vaccines containing
protein distribution
protein
Prior art date
Application number
CY20121100147T
Other languages
English (en)
Inventor
Nathalie Garcon
Catherine Marie Ghislaine Gerard
Jean Stephenne
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0025574A external-priority patent/GB0025574D0/en
Priority claimed from GB0025573A external-priority patent/GB0025573D0/en
Priority claimed from US09/690,921 external-priority patent/US6544518B1/en
Priority claimed from EP07121675A external-priority patent/EP1889630B1/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1112658T1 publication Critical patent/CY1112658T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Permanent Magnet Type Synchronous Machine (AREA)
  • Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει νέες τυποποιήσεις ανοσοενισχυτικού εκδόχου για χρήση με καρκινικά αντιγόνα. Το ανοσοενισχυτικό έκδοχο περιέχει μια σαπωνίνη και ένα ανοσοδιεγερτικό ολιγονουκλεοτίδιο.
CY20121100147T 2000-10-18 2012-02-14 Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d CY1112658T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0025574A GB0025574D0 (en) 2000-10-18 2000-10-18 Vaccine
GB0025573A GB0025573D0 (en) 2000-10-18 2000-10-18 Vaccine
US09/690,921 US6544518B1 (en) 1999-04-19 2000-10-18 Vaccines
EP07121675A EP1889630B1 (en) 2000-10-18 2001-10-16 Vaccines comprising MAGE antigen linked to protein D fragment

Publications (1)

Publication Number Publication Date
CY1112658T1 true CY1112658T1 (el) 2016-02-10

Family

ID=34082077

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20081100112T CY1108526T1 (el) 2000-10-18 2008-01-31 Εμβολια εναντι καρκινων
CY20121100147T CY1112658T1 (el) 2000-10-18 2012-02-14 Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
CY20121101024T CY1113735T1 (el) 2000-10-18 2012-10-26 Εμβολια ογκου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20081100112T CY1108526T1 (el) 2000-10-18 2008-01-31 Εμβολια εναντι καρκινων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121101024T CY1113735T1 (el) 2000-10-18 2012-10-26 Εμβολια ογκου

Country Status (14)

Country Link
US (1) US20050019340A1 (el)
EP (1) EP2266603B1 (el)
JP (1) JP2008285487A (el)
KR (1) KR100831139B1 (el)
AT (1) ATE534401T1 (el)
CY (3) CY1108526T1 (el)
DE (1) DE60131670T2 (el)
DK (2) DK2266603T3 (el)
ES (2) ES2377077T3 (el)
HK (3) HK1057992A1 (el)
IL (1) IL155282A (el)
PL (1) PL211151B1 (el)
PT (3) PT1889630E (el)
SI (1) SI2266603T1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU761899B2 (en) 1998-05-22 2003-06-12 Ottawa Health Research Institute Methods and products for inducing mucosal immunity
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP1578954A4 (en) * 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1623715B1 (en) * 2004-07-13 2012-09-19 Charité - Universitätsmedizin Berlin A composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
EP0341252B1 (en) 1987-01-07 1997-11-19 Imperial Cancer Research Technology Limited Human polymorphic epithelial mucin polypeptides for use in therapy and diagnosis
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
DK0761231T3 (da) 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
DE69405551T3 (de) * 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
WO1995014026A1 (en) 1993-11-17 1995-05-26 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5668267A (en) 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
AU3399197A (en) 1996-06-18 1998-01-07 Alza Corporation Device for enhancing transdermal agent delivery or sampling
ES2242226T3 (es) 1996-07-03 2005-11-01 Eisai Co., Ltd. Composiciones que contienen analogos del lipido a y procedimiento parasu preparacion.
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
AU4992197A (en) 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
CA2271167C (en) 1996-12-20 2007-01-09 Alza Corporation Device and method for enhancing transdermal agent flux
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
EP1630235A3 (en) 1997-02-25 2009-05-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and method for their use
JP3036686B2 (ja) 1997-02-27 2000-04-24 政夫 高橋 冠状動脈のバイパス手術に用いる血管吻合部の止血保持装置
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2227825T3 (es) 1997-04-01 2005-04-01 Corixa Corporation Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
ZA982968B (en) 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
US6130043A (en) 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
JP5220248B2 (ja) 1997-08-29 2013-06-26 アンチジェニックス・インコーポレイテッド アジュバントｑｓ−２１および賦形剤としてポリソルベートまたはシクロデキストリンを含む組成物
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
JP2001520011A (ja) 1997-09-26 2001-10-30 コリクサ コーポレイション ヒトガンについてのマウスモデル
HUP0101139A3 (en) 1997-12-02 2003-11-28 Powderject Vaccines Inc Madiso Transdermal delivery of particulate vaccine compositions
WO1999033869A2 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
DK1584685T3 (da) 1998-02-05 2011-07-11 Glaxosmithkline Biolog Sa Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
WO1999053061A2 (en) 1998-04-15 1999-10-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
AU761899B2 (en) * 1998-05-22 2003-06-12 Ottawa Health Research Institute Methods and products for inducing mucosal immunity
EP1870466A3 (en) 1998-07-14 2008-03-19 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
CA2340174C (en) * 1998-08-10 2011-01-04 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
US6695227B1 (en) 1999-01-18 2004-02-24 Earth Chemical Co., Ltd. Aerosol spraying apparatus
IL144371A0 (en) 1999-01-29 2002-05-23 Corixa Corp Her-2/neu fusion proteins
WO2000052165A2 (en) 1999-03-04 2000-09-08 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
GB9905124D0 (en) * 1999-03-05 1999-04-28 Smithkline Beecham Biolog Novel compounds
IL145982A0 (en) * 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2001002828A2 (en) * 1999-07-07 2001-01-11 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
WO2001062778A2 (en) * 2000-02-23 2001-08-30 Smithkline Beecham Biologicals S.A. Tumour-specific animal proteins
SG176220A1 (en) * 2009-05-27 2011-12-29 Glaxosmithkline Biolog Sa Casb7439 constructs

Also Published As

Publication number Publication date
US20050019340A1 (en) 2005-01-27
ES2392943T3 (es) 2012-12-17
HK1117729A1 (en) 2009-01-23
EP2266603B1 (en) 2012-09-12
HK1147673A1 (en) 2011-08-19
CY1113735T1 (el) 2016-06-22
KR20030044015A (ko) 2003-06-02
EP2266603A1 (en) 2010-12-29
ATE534401T1 (de) 2011-12-15
IL155282A (en) 2010-11-30
PT1326638E (pt) 2008-02-06
PT1889630E (pt) 2012-02-29
KR100831139B1 (ko) 2008-05-20
PT2266603E (pt) 2012-11-02
CY1108526T1 (el) 2014-04-09
DK2266603T3 (da) 2012-11-05
JP2008285487A (ja) 2008-11-27
ES2377077T3 (es) 2012-03-22
DK1889630T3 (da) 2012-03-05
HK1057992A1 (en) 2004-04-30
SI2266603T1 (sl) 2012-12-31
DE60131670D1 (de) 2008-01-10
DE60131670T2 (de) 2008-10-30
PL211151B1 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
NO20015073L (no) Vaksiner
CY1114333T1 (el) Αντιγονα του neisseria meningitidis
CY1107561T1 (el) Εμβoλιο kata του πνευμονιοκοκκου
DE60012711D1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
CY1113078T1 (el) Συνθεση πολυσθενους εμβολιου
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
CY1115842T1 (el) Συμπληρωμενο ομv εμβολιο κατα μηνιγγιtiδοκοκκου
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
NO20023935L (no) Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
DE60226175D1 (de) Mycobakterieller impfstoff
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
SE9600646D0 (sv) Vaccin
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους